Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664595 | 0.98 | HRH3 (0.52) | HRH3HRH1PARP1CYP2D6KLKB1 | |
| SCHEMBL5663170 | 0.88 | HRH3 (0.51) | HRH3HRH1PARP1CYP2D6 | |
| SCHEMBL5171095 | 0.86 | HRH3 (0.55) | HRH3HRH1CYP2D6 | |
| SCHEMBL5184270 | 0.86 | HRH3 (0.55) | HRH3HRH1CYP2D6 | |
| SCHEMBL5663223 | 0.84 | HRH3 (0.58) | HRH3HRH1CYP2D6 | |
| SCHEMBL5665400 | 0.83 | HRH3 (0.57) | HRH3HRH1CYP2D6 | |
| SCHEMBL1792027 | 0.82 | KLKB1 (0.49) | HRH3HRH1KLKB1KLK1 | |
| SCHEMBL5660108 | 0.81 | HRH3 (0.63) | HRH3HRH1CYP2D6 | |
| SCHEMBL5172493 | 0.80 | HRH3 (0.48) | HRH3HRH1CYP2D6 | |
| SCHEMBL5172739 | 0.78 | HRH3 (0.54) | HRH3HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885PARP1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.